BioMedLib Search Engine [ goto HOMEPAGE ]

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Solitary concomitant endocrine tumor and ductal adenocarcinoma of pancreas.

Pancreatic tumors with combined exocrine and endocrine features are rare.

Most reported cases are classified as mixed exocrine and endocrine carcinoma of the pancreas.

We report the first case of solitary concomitant endocrine tumor and ductal adenocarcinoma of the pancreas.

The tumor was fortuitously discovered in the pancreatic tail after a tumor survey panel.

The exocrine part showed a poorly-differentiated adenocarcinoma.

We reviewed the literature on pancreatic tumors with combined exocrine and endocrine features.

[MeSH-major] Adenocarcinoma / pathology. Carcinoma, Pancreatic Ductal / pathology. Endocrine Gland Neoplasms / pathology. Pancreatic Neoplasms / pathology

MedlinePlus Health Information. consumer health - Pancreatic Cancer.

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Cites] West J Med. 1986 Jun;144(6):746-9 [3014756.001]

[Cites] Cancer. 1984 Nov 1;54(9):1766-70 [6089999.001]

[Cites] J Gastroenterol. 1997 Aug;32(4):562-5 [9250909.001]

[Cites] Int J Pancreatol. 1999 Apr;25(2):77-87 [10360219.001]

[Cites] Virchows Arch. 2004 Sep;445(3):231-5 [15517367.001]

[Cites] Pancreas. 2005 Jul;31(1):79-83 [15968252.001]

[Cites] JOP. 2005 Sep;6(5):449-54 [16186667.001]

[Cites] Pancreatology. 2006;6(6):520-6 [17124434.001]

[Cites] Gastroenterology. 2008 Apr;134(4):981-7 [18395079.001]

[Cites] Arch Pathol Lab Med. 2000 Feb;124(2):284-6 [10656740.001]

[Cites] Int J Pancreatol. 2000 Jun;27(3):249-57 [10952408.001]

[Cites] Surg Today. 2001;31(2):177-9 [11291717.001]

[Cites] Histopathology. 2002 Aug;41(2):122-6 [12147089.001]

[Cites] Hepatobiliary Pancreat Dis Int. 2004 Aug;3(3):473-5 [15313692.001]

[Cites] Hum Pathol. 1982 Mar;13(3):263-71 [7076209.001]

[Cites] J Korean Med Sci. 1996 Apr;11(2):188-92 [8835769.001]

(PMID = 20518094.001).

[ISSN] 2219-2840

[Journal-full-title] World journal of gastroenterology

[ISO-abbreviation] World J. Gastroenterol.

[Language] eng

[Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't

[Publication-country] China

[Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Chromogranin A; 0 / Hypoglycemic Agents; 0 / Synaptophysin; 9007-92-5 / Glucagon

[Other-IDs] NLM/ PMC2880785

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] [Two cases of pancreatic ductal adenocarcinoma, manifested as solid pseudopapillary tumor and intraductal papillary mucinous neoplasm].

Compared with other types of cancers, pancreatic cancer is one of the most dreadful malignancies and is fifth leading cause of cancer-related death in Korea.

It is difficult to expect early diagnosis or improvement in prognosis due to lack of specific early symptoms and effective diagnostic methods.

Whereas cystic neoplasm of the pancreas is a rare type of pancreatic tumor, surgical resection provides good prognosis because of its low possibility of local invasion or distant metastasis.

In case of pancreatic cystic tumor, radiologic differentiation between benign and malignant lesions is crucial for the selection of appropriate treatment and the prediction of prognosis.

And ductal adenocarcinoma of pancreas presenting in cystic form is an uncommon type of cystic tumor, making it extremely rare among all pancreatic malignancies.

We report two cases of atypical pancreatic ductal adenocarcinoma presenting as solid pseudopapillary tumor and intraductal papillary mucinous neoplasm, respectively.

[MeSH-major] Adenocarcinoma, Mucinous / diagnosis. Adenocarcinoma, Papillary / diagnosis. Carcinoma, Pancreatic Ductal / diagnosis. Pancreatic Neoplasms / diagnosis

MedlinePlus Health Information. consumer health - Pancreatic Cancer.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 18349578.001).

[ISSN] 1598-9992

[Journal-full-title] The Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi

[ISO-abbreviation] Korean J Gastroenterol

[Language] kor

[Publication-type] Case Reports; English Abstract; Journal Article

[Publication-country] Korea (South)

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

A 65-year-old man was given the first-line treatment with gemcitabine for the advanced adenocarcinoma of pancreas.

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Cites] Ann Oncol. 2000 Sep;11(9):1191-4 [11061617.001]

[Cites] Mund Kiefer Gesichtschir. 2002 Sep;6(5):331-5 [12448236.001]

[Cites] J Rheumatol. 2003 Jun;30(6):1341-3 [12784412.001]

[Cites] Rheum Dis Clin North Am. 2003 May;29(2):293-313 [12841296.001]

[Cites] Eur J Cancer Care (Engl). 2010 May;19(3):408-9 [19490003.001]

[Cites] Clin Ter. 2003 May-Jun;154(3):207-10 [12910811.001]

[Cites] Anticancer Drugs. 2003 Nov;14(10):829-32 [14597878.001]

[Cites] Neoplasma. 2004;51(5):334-40 [15640936.001]

[Cites] J Mal Vasc. 2005 Feb;30(1):53-7 [15924070.001]

[Cites] Nephrol Dial Transplant. 2006 Nov;21(11):3038-45 [16968717.001]

[Cites] Pain Physician. 2008 Jan;11(1):91-6 [18196175.001]

[Cites] Expert Opin Drug Saf. 2008 Nov;7(6):703-16 [18983217.001]

(PMID = 22933925.001).

[ISSN] 1581-3207

[Journal-full-title] Radiology and oncology

[ISO-abbreviation] Radiol Oncol

[Language] eng

[Publication-type] Journal Article

[Publication-country] Slovenia

[Other-IDs] NLM/ PMC3423709

[Keywords] NOTNLM ; chemotherapy / digital ischemic events / gemcitabine vascular toxicity

   

Advertisement

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Surgical resectability of pancreatic adenocarcinoma: CTA.

Imaging studies play an important role in the diagnosis and management of patients with pancreatic adenocarcinoma.

Meticulous technique following a well-designed pancreas protocol is essential for maximizing the diagnostic efficacy of CT.

After the diagnosis of pancreatic adenocarcinoma is made, the key to management is staging to determine resectability.

[MeSH-major] Adenocarcinoma / radiography. Pancreatic Neoplasms / radiography. Tomography, X-Ray Computed

MedlinePlus Health Information. consumer health - CT Scans.

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Cites] Radiology. 1999 Nov;213(2):468-72 [10551228.001]

[Cites] Radiology. 2009 Mar;250(3):758-65 [19164113.001]

[Cites] AJR Am J Roentgenol. 1999 Dec;173(6):1513-8 [10584794.001]

[Cites] J Comput Assist Tomogr. 2001 May-Jun;25(3):337-42 [11351180.001]

[Cites] Radiology. 2001 Jul;220(1):97-102 [11425979.001]

[Cites] AJR Am J Roentgenol. 2002 Apr;178(4):821-6 [11906855.001]

[Cites] J Gastrointest Surg. 2001 Nov-Dec;5(6):626-33 [12086901.001]

[Cites] Radiology. 2002 Sep;224(3):764-8 [12202711.001]

[Cites] AJR Am J Roentgenol. 2003 Feb;180(2):475-80 [12540455.001]

[Cites] AJR Am J Roentgenol. 2003 May;180(5):1217-24 [12704026.001]

[Cites] Radiology. 2003 Oct;229(1):81-90 [14519871.001]

[Cites] AJR Am J Roentgenol. 2004 Mar;182(3):619-23 [14975959.001]

[Cites] AJR Am J Roentgenol. 1988 May;150(5):1035-41 [3258703.001]

[Cites] Radiology. 1995 Nov;197(2):381-5 [7480681.001]

[Cites] Radiology. 1996 Jun;199(3):697-701 [8637990.001]

[Cites] Abdom Imaging. 1996 May-Jun;21(3):202-6 [8661548.001]

[Cites] AJR Am J Roentgenol. 1997 Apr;168(4):971-7 [9124153.001]

[Cites] AJR Am J Roentgenol. 1997 Jun;168(6):1439-43 [9168704.001]

[Cites] Radiology. 1998 Feb;206(2):373-8 [9457188.001]

[Cites] AJR Am J Roentgenol. 1998 May;170(5):1315-22 [9574609.001]

[Cites] Radiology. 1999 Jan;210(1):71-4 [9885589.001]

[Cites] Ann Intern Med. 2004 Nov 16;141(10):753-63 [15545675.001]

[Cites] J Comput Assist Tomogr. 2005 Mar-Apr;29(2):170-5 [15772532.001]

[Cites] J Comput Assist Tomogr. 2005 Jul-Aug;29(4):438-45 [16012297.001]

[Cites] Best Pract Res Clin Gastroenterol. 2006 Apr;20(2):349-64 [16549332.001]

[Cites] AJR Am J Roentgenol. 2006 Dec;187(6):1513-20 [17114545.001]

[Cites] Abdom Imaging. 2006 Sep-Oct;31(5):568-74 [16465578.001]

[Cites] Cancer. 2007 Aug 15;110(4):738-44 [17580363.001]

[Cites] AJR Am J Roentgenol. 2007 Nov;189(5):1044-50 [17954638.001]

[Cites] Radiographics. 2007 Nov-Dec;27(6):1653-66 [18025509.001]

[Cites] Radiology. 2007 Dec;245(3):770-8 [17951353.001]

[Cites] CA Cancer J Clin. 2008 Mar-Apr;58(2):111-25 [18272835.001]

[Cites] AJR Am J Roentgenol. 1999 Dec;173(6):1509-12 [10584793.001]

(PMID = 19468791.001).

[ISSN] 1432-0509

[Journal-full-title] Abdominal imaging

[ISO-abbreviation] Abdom Imaging

[Language] eng

[Publication-type] Journal Article

[Publication-country] United States

[Other-IDs] NLM/ PMC2900587

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Cystic ductal adenocarcinoma of pancreas: an unusual variant.

Cystic lesions of the pancreas are usually pseudocysts (90%); only 10% of them are cystic tumors.

These cystic tumors constitute less than 10% of all pancreatic neoplasms, making them an extremely uncommon type of pancreatic malignancy.

Ductal adenocarcinoma of pancreas presenting in cystic form is an uncommon type of cystic tumor, making it extremely rare among all pancreatic malignancies (solid or cystic).

The review of literature concerning the diagnosis and management has also been discussed.

[MeSH-major] Carcinoma, Pancreatic Ductal / pathology. Pancreatic Neoplasms / pathology

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 17310557.001).

[ISSN] 0250-636X

[Journal-full-title] Tropical gastroenterology : official journal of the Digestive Diseases Foundation

[ISO-abbreviation] Trop Gastroenterol

[Language] eng

[Publication-type] Case Reports; Journal Article

[Publication-country] India

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Intestinal autotransplantation for adenocarcinoma of pancreas involving the mesenteric root: our experience and literature review.

Ductal adenocarcinoma of pancreas represents one of the most aggressive tumor as demonstrated by 3- and 5-year survival rates.

We describe 2 cases of adenocarcinoma of pancreas involving mesenteric root treated by small-bowel autotransplantation.

Intestinal autotransplantation can represent a significant technical advance for increasing the resectability rate and, ultimately, the survival rate for advanced adenocarcinoma of the pancreas in highly selected patients.

[MeSH-major] Adenocarcinoma / surgery. Intestine, Small / transplantation. Pancreatic Neoplasms / surgery

[MeSH-minor] Adult. Carcinoma, Pancreatic Ductal / pathology. Carcinoma, Pancreatic Ductal / surgery. Humans. Male. Mesenteric Artery, Superior / pathology. Mesenteric Artery, Superior / surgery. Mesenteric Veins / pathology. Mesenteric Veins / surgery. Middle Aged. Transplantation, Autologous

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 17312468.001).

[ISSN] 1536-4828

[Journal-full-title] Pancreas

[ISO-abbreviation] Pancreas

[Language] eng

[Publication-type] Case Reports; Journal Article; Review

[Publication-country] United States

[Number-of-references] 6

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Expression of K homology domain containing protein overexpressed in cancer in pancreatic FNA for diagnosing adenocarcinoma of pancreas.

We evaluated the immunocytochemical (ICC) expression of K homology domain containing protein overexpressed in cancer (KOC) in pancreatic endoscopic ultrasound-guided fine needle aspirates (EUS-FNAs) to assess its potential use as an adjunct in differentiating nonneoplastic (GI epithelium) and benign neoplastic epithelia (benign epithelial pancreatic neoplasms) from pancreatic adenocarcinoma cells.

We conclude that KOC ICC expression on alcohol-fixed smears along with cytology improves the sensitivity of EUS-FNAs in the diagnosis of pancreatic Ac, and KOC reactivity is especially useful in differentiating Ac from nonneoplastic gastrointestinal epithelium and benign neoplastic epithelia.

[MeSH-major] Adenocarcinoma / diagnosis. Biopsy, Fine-Needle. Neoplasm Proteins / analysis. Pancreatic Neoplasms / diagnosis. RNA-Binding Proteins / analysis

[MeSH-minor] Adult. Aged. Aged, 80 and over. Diagnosis, Differential. Endosonography. Female. Humans. Male. Middle Aged. Sensitivity and Specificity

Genetic Alliance. consumer health - Pancreatic cancer.

MedlinePlus Health Information. consumer health - Pancreatic Cancer.

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Copyright] (c) 2007 Wiley-Liss, Inc.

(PMID = 17924416.001).

[ISSN] 8755-1039

[Journal-full-title] Diagnostic cytopathology

[ISO-abbreviation] Diagn. Cytopathol.

[Language] eng

[Publication-type] Evaluation Studies; Journal Article

[Publication-country] United States

[Chemical-registry-number] 0 / IMP3 protein, human; 0 / Neoplasm Proteins; 0 / RNA-Binding Proteins

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Extended resection for pancreatic adenocarcinoma.

Adenocarcinoma of the pancreas presents a number of therapeutic challenges.

TP should not be performed for most cases of adenocarcinoma of the pancreatic head because of the nominal incidence of lymph node involvement along the body and tail of the pancreas, the scarcity of multicentric disease, and the better management of pancreatic leaks after PD.

The disappointing experience with extended resections underscores the need for better adjuvant systemic strategies and the interdisciplinary care of patients with pancreatic adenocarcinoma.

[MeSH-major] Adenocarcinoma / surgery. Pancreatic Neoplasms / surgery

MedlinePlus Health Information. consumer health - Pancreatic Cancer.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 17602057.001).

[ISSN] 1083-7159

[Journal-full-title] The oncologist

[ISO-abbreviation] Oncologist

[Language] eng

[Publication-type] Journal Article; Review

[Publication-country] United States

[Number-of-references] 55

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Umbilical Hernia Repair in Patient with Ascites with Incidental Finding of Pancreatic Adenocarcinoma Metastasis in Hernia Sac.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 28958238.001).

[ISSN] 1555-9823

[Journal-full-title] The American surgeon

[ISO-abbreviation] Am Surg

[Language] eng

[Publication-type] Journal Article

[Publication-country] United States

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] [Serum tumor markers at exocrine adenocarcinoma of pancreas].

[Transliterated title] Sérové nádorové markery u exokrinních adenokarcinomů pankreatu.

Pancreatic cancer represents a group of cancers with the worst prognosis.

Only early diagnosis can ensure better therapy results.

Possibility of early diagnosis based on imaging and endoscope methods is at present very limited due to the anatomical location of pancreas.

Serum tumor markers assessment might represent one of the possibilities of early detection of the pancreatic cancer.

Review summarizes current knowledge on the use of tumor markers for diagnosis, prognosis and therapy monitoring of pancreatic exocrine adenocarcinomas with respect to the clinical use at the daily routine practice.

[MeSH-major] Adenocarcinoma / diagnosis. Biomarkers, Tumor / blood. Pancreatic Neoplasms / diagnosis

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 15807292.001).

[ISSN] 0008-7335

[Journal-full-title] Casopís lékar̆ů c̆eských

[ISO-abbreviation] Cas. Lek. Cesk.

[Language] cze

[Publication-type] English Abstract; Journal Article; Review

[Publication-country] Czech Republic

[Chemical-registry-number] 0 / Biomarkers, Tumor

[Number-of-references] 18

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Usefulness of S100P in diagnosis of adenocarcinoma of pancreas on fine-needle aspiration biopsy specimens.

Even though the cytologic criteria for pancreatic ductal adenocarcinoma (PDA) on fine-needle aspiration biopsy (FNAB) specimens have been well defined, a diagnostic challenge is still present.

We immunohistochemically evaluated the diagnostic value of S100P on cell-block and/or smear preparations in 58 cases of FNAB specimens of the pancreas.

The 58 cases were divided into 4 groups: 1, 32 cases of PDA; 2, 6 cases with an atypical or "suspicious" diagnosis; 3, 14 cases of benign or reactive ductal epithelium; and 4, 6 cases of endocrine tumor.

[MeSH-major] Biomarkers, Tumor / metabolism. Carcinoma, Pancreatic Ductal / diagnosis. Carrier Proteins / metabolism. Nuclear Proteins / metabolism. Pancreatic Neoplasms / diagnosis

[MeSH-minor] Adenoma, Islet Cell / diagnosis. Adenoma, Islet Cell / metabolism. Biopsy, Fine-Needle. Carcinoma, Islet Cell / diagnosis. Carcinoma, Islet Cell / metabolism. Diagnosis, Differential. Epithelial Cells / metabolism. Epithelial Cells / pathology. Humans. Immunoenzyme Techniques. Islets of Langerhans / metabolism. Islets of Langerhans / pathology. Pancreatic Ducts / metabolism. Pancreatic Ducts / pathology

MedlinePlus Health Information. consumer health - Pancreatic Cancer.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 18089492.001).

[ISSN] 0002-9173

[Journal-full-title] American journal of clinical pathology

[ISO-abbreviation] Am. J. Clin. Pathol.

[Language] eng

[Publication-type] Journal Article

[Publication-country] United States

[Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Carrier Proteins; 0 / Nuclear Proteins; 0 / S100PBP protein, human

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

This investment has already given some benefits since some of these inhibitors show potent chemotherapeutic efficacy against a wide range of tumours such as non-small cell lung cancer, adenocarcinoma of pancreas, bladder cancer, leukaemia and some solid tumours.

NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 15974997.001).

[ISSN] 0929-8673

[Journal-full-title] Current medicinal chemistry

[ISO-abbreviation] Curr. Med. Chem.

[Language] eng

[Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review

[Publication-country] Netherlands

[Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Enzyme Inhibitors; 0 / Ribonucleotides; EC 1.17.4.- / Ribonucleotide Reductases

[Number-of-references] 172

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

It is frequently observed in patients with breast carcinoma as well as adenocarcinoma of pancreas, rectum, lung, ovary and parotid gland.

Genetic Alliance. consumer health - Carcinoma, Squamous Cell.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 16115190.001).

[ISSN] 1368-5031

[Journal-full-title] International journal of clinical practice

[ISO-abbreviation] Int. J. Clin. Pract.

[Language] eng

[Publication-type] Case Reports; Journal Article; Review

[Publication-country] England

[Number-of-references] 13

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Rash as a marker for the efficacy of gemcitabine plus erlotinib-based therapy in pancreatic cancer: Results from the AViTA Study.

: 4532 Background: The EGFR inhibitor, erlotinib (E), in combination with gemcitabine (G), provides a significant survival benefit in metastatic pancreatic cancer.

METHODS: Chemo-naïve patients (pts) with metastatic pancreatic adenocarcinoma and KPS of 60-100 were randomized to GE-placebo (GE-P) or GE-B; pts received B/P 5mg/kg q2w plus E (100mg/d) and G (1,000mg/m^²) given weekly for 7 weeks during the first 8-weekly cycle, followed by weekly for 3 weeks during subsequent 4-weekly cycles.

JCO 2007), in pts with advanced pancreatic cancer.

Studies are under way to prospectively investigate the relationship between rash and efficacy with erlotinib-based regimens in pancreatic cancer.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 27962994.001).

[ISSN] 1527-7755

[Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology

[ISO-abbreviation] J. Clin. Oncol.

[Language] eng

[Publication-type] Journal Article

[Publication-country] United States

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Detection of circulating hypoxia-regulated miR-210 in pancreatic adenocarcinoma patients.

Moreover, since pancreatic adenocarcinomas have been previously shown to be extremely hypoxic, we hypothesized that miR-210 may be elevated in the plasma of these patients compared to non-cancer controls.

Here, we compared the circulating plasma levels of miR-210 in pancreatic cancer patients and controls using a novel miRNA extraction approach and quantitative PCR.

METHODS: Pretreatment EDTA plasma samples were obtained from pancreatic cancer patients and age-matched non-cancer controls. miRNA was extracted from 40ul of plasma and reverse transcribed to cDNA.

The procedure was performed on the initial 11 pairs of age-matched pancreatic cancer patients and non- cancer controls, then validated with a second cohort of 12 pancreatic cancer patients and 11 controls.

There is a statistically significant four-fold increase of mir-210 expression in pancreatic cancer patients compared to normal controls (Student's t-test, p <0.0001).

Its expression is significantly higher in the blood of pancreatic cancer patients compared to controls and may potentially serve as a useful biomarker for pancreatic cancer diagnosis.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 27964211.001).

[ISSN] 1527-7755

[Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology

[ISO-abbreviation] J. Clin. Oncol.

[Language] eng

[Publication-type] Journal Article

[Publication-country] United States

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Safety and tolerability of combined gemcitabine (G) and erlotinib (E) plus sorafenib (S) in the first-line treatment of metastatic pancreatic cancer.

: e15594 Background: The addition of E to G results in improved survival for patients(pts) with locally advanced and metastatic pancreatic cancer.

Many pancreatic tumors have constitutively activated ras/raf pathways and overexpress VEGF.

Sorafenib, a multitargeted tyrosine kinase inhibitor which targets VEGR 1-3, PDGFR-α and β and the RAF/MEK/ERK pathway, when combined with G and E may synergize with these agents resulting in a more complete blockade of the signal transduction cascade in pancreatic cancer growth and progression and therefore improve outcome.

METHODS: Pts with previously untreated, histologically confirmed, unresectable pancreatic adenocarcinoma, ECOG PS 0-1, and adequate organ function were eligible and received G 1,000 mg/m² over 30 min weekly × 3 every 4 weeks.

CONCLUSIONS: The combination of G and E plus S in the treatment of advanced pancreatic cancer is a well tolerated regimen without significant increased toxicity as compared to gemcitabine alone, except for very manageable cutaneous reactions.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 27962883.001).

[ISSN] 1527-7755

[Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology

[ISO-abbreviation] J. Clin. Oncol.

[Language] eng

[Publication-type] Journal Article

[Publication-country] United States

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] A randomized phase II trial of adjuvant chemotherapy with cisplatin, epirubicin, 5-fluorouracil, gemcitabine (PEFG regimen) or gemcitabine alone after curative resection for pancreatic cancer.

: 4608 Background: The PEFG regimen yielded a statistically relevant outcome advantage as compared with gemcitabine (G) in patients with advanced pancreatic adenocarcinoma (PA).

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 27964177.001).

[ISSN] 1527-7755

[Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology

[ISO-abbreviation] J. Clin. Oncol.

[Language] eng

[Publication-type] Journal Article

[Publication-country] United States

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Phase II trial of GTX chemotherapy in metastatic pancreatic cancer.

This GTX regimen was designed to inhibit MEK-ERK phosphorylation and increase BAX and BAK and also decrease BCL-2 in pancreatic cancer cell lines.

Based on these findings, we pursued a prospective clinical trial evaluating the activity of GTX in previously untreated patients with metastatic pancreatic cancer.

METHODS: Patients with histologically confirmed metastatic adenocarcinoma of the pancreas, median age 60, 63% male, ECOG PS 0-2, received capecitabine 1500mg/m2/day total orally in divided doses, days 1 thru 14, gemcitabine 750mg/m2 IV over 75 minutes followed by docetaxel 30mg/m2 IV on days 4 and 11 on a 21 day cycle.

CONCLUSIONS: The combination of gemcitabine, docetaxel, and capecitabine has activity in metastatic pancreatic cancer with a median survival over 1 year.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 27964215.001).

[ISSN] 1527-7755

[Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology

[ISO-abbreviation] J. Clin. Oncol.

[Language] eng

[Publication-type] Journal Article

[Publication-country] United States

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] A randomized phase II study of FOLFOX or FOLFIRI.3 as second-line therapy in patients with advanced pancreatic cancer previously treated with gemcitabine-based chemotherapy.

: 4618 Background: Only few clinical trials have been conducted in patients with advanced pancreatic cancer after failure of first-line gemcitabine-based chemotherapy.

We conducted a randomized phase II trial of modified FOLFOX vs. modified FOLFIRI.3 as second-line regimen for the patients with gemcitabine refractory pancreatic cancer ( NCT00786006 ).

METHODS: Patients with advanced pancreatic adenocarcinoma previously treated with gemcitabine were randomly assigned to FOLFOX or FOLFIRI.3 stratifying by age (≤ 65 vs. >65), performance status (0-1 vs. 2) and prior response to gemcitabine (PR/SD vs. PD).

CONCLUSIONS: Both FOLFOX and FOLFIRI.3 were tolerated with manageable toxicity, offering modest activity as second-line treatment of patients with advanced or metastatic pancreatic cancer, previously treated with gemcitabine.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 27964179.001).

[ISSN] 1527-7755

[Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology

[ISO-abbreviation] J. Clin. Oncol.

[Language] eng

[Publication-type] Journal Article

[Publication-country] United States

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

No objective responses were seen but 3 pts with pancreatic adenocarcinoma, hepatocarcinoma and lower esophagus adenocarcinoma presented stable disease lasting >3 months.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 27961881.001).

[ISSN] 1527-7755

[Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology

[ISO-abbreviation] J. Clin. Oncol.

[Language] eng

[Grant] United States / NCI NIH HHS / CA / P30 CA008748

[Publication-type] Journal Article

[Publication-country] United States

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Prevalence of depression, sleep-related disturbances, and anxiety and their effect on quality of life in patients with adenocarcinoma of the pancreas.

: e15678 Purpose: To evaluate the prevalence of depression, sleep related disturbances and anxiety and their effect on quality of life in patients with recently diagnosed adenocarcinoma of the pancreas who present to a multidisciplinary pancreatic cancer clinic.

A minority (2 pts, 8%) had PSWQ scores characteristic of an anxiety disorder, while 33% (8 pts) had moderate anxiety scores.

CONCLUSIONS: Our results indicate that mild to moderate depressive symptoms, anxiety and potential sleep problems are common in patients referred to a multidisciplinary pancreatic cancer clinic.

To better characterize the relationship of depression (and potential causes) with pancreatic cancer, additional prospective longitudinal studies are needed.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 27962819.001).

[ISSN] 1527-7755

[Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology

[ISO-abbreviation] J. Clin. Oncol.

[Language] eng

[Publication-type] Journal Article

[Publication-country] United States

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Longitudinal analysis of quality of life (QoL) within a randomized phase III trial in patients (pts) with metastatic pancreatic adenocarcinoma (MPA).

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 27963761.001).

[ISSN] 1527-7755

[Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology

[ISO-abbreviation] J. Clin. Oncol.

[Language] eng

[Publication-type] Journal Article

[Publication-country] United States

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Impact of first-line and second-line PFS definitions within a randomized phase III trial in patients (pts) with metastatic pancreatic adenocarcinoma (MPA).

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 27962358.001).

[ISSN] 1527-7755

[Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology

[ISO-abbreviation] J. Clin. Oncol.

[Language] eng

[Publication-type] Journal Article

[Publication-country] United States

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] A randomized trial of gemcitabine (G) versus G plus cisplatin in chemotherapy-naive advanced pancreatic adenocarcinoma: The GIP-1 (Gruppo Italiano Pancreas- GOIM/GISCAD/GOIRC) study.

: 4504 Background: Single-agent gemcitabine (G) remains standard treatment for advanced pancreatic adenocarcinoma (APC).

METHODS: Patients (pts) with locally advanced and/or metastatic pancreatic adenocarcinoma, age 18-75, Karnofsky Performance Status (KPS) ≥50, were randomized to receive G (arm A) or G+P (arm B).

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 27962688.001).

[ISSN] 1527-7755

[Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology

[ISO-abbreviation] J. Clin. Oncol.

[Language] eng

[Publication-type] Journal Article

[Publication-country] United States

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] A randomized phase II trial of two different four-drug combinations in advanced pancreatic adenocarcinoma: Cisplatin, capecitabine, gemcitabine plus either epirubicin or docetaxel.

: 4614 Background: The combination of cisplatin (P), epirubicin (E), 5-fluorouracil (F) and gemcitabine (G) (PEFG regimen) yielded a progression-free survival at 6 months from treatment start (PFS6) of about 50% and a 1-year overall survival (OS) around 40% in patients with advanced pancreatic adenocarcinoma (PA).

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 27964185.001).

[ISSN] 1527-7755

[Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology

[ISO-abbreviation] J. Clin. Oncol.

[Language] eng

[Publication-type] Journal Article

[Publication-country] United States

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Preoperative gemcitabine based chemoradiotherapy in locally advanced nonmetastatic pancreatic adenocarcinoma.

: e15677 Background: Almost 30% of patients with pancreatic cancer present with locally advanced tumours in absence of distant metastasis.

The combination of gemcitabine with concurrent radiation therapy is a promising approach that is being investigated in patients' unresectable pancreatic cancer.

AIM OF THE WORK: The efficacy of preoperative gemcitabine based chemo-radiotherapy in increasing the resectability rate for patients locally advanced, non metastatic pancreatic cancer was assessed.

CONCLUSIONS: preoperative gemcitabine based chemoradiation might benefit patients with locally advanced non metastatic pancreatic cancer by increasing the resectability without significant acute toxicity.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 27962829.001).

[ISSN] 1527-7755

[Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology

[ISO-abbreviation] J. Clin. Oncol.

[Language] eng

[Publication-type] Journal Article

[Publication-country] United States

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Correlation of CXCR4 expression in resected pancreatic adenocarcinoma (PA) with relapse and survival after adjuvant radiochemotherapy (RCT).

This chemoreceptor could be implicated in the resistance of pancreatic cancer cells to RCT and its targeted inhibition deserves clinical evaluation.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 27963130.001).

[ISSN] 1527-7755

[Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology

[ISO-abbreviation] J. Clin. Oncol.

[Language] eng

[Publication-type] Journal Article

[Publication-country] United States

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

Antitumor activity was assessed in an allogeneic model utilizing murine JC mammary adenocarcinoma cells growing in Balb/c mice, and a xenograft model of human Bxpc pancreatic adenocarcinoma cells growing in scid-mice.

CONCLUSIONS: These newly developed SK inhibitors provide orally-available drug candidates for the treatment of pancreatic cancer and other diseases.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 27964127.001).

[ISSN] 1527-7755

[Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology

[ISO-abbreviation] J. Clin. Oncol.

[Language] eng

[Publication-type] Journal Article

[Publication-country] United States

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] A phase II trial of erlotinib in combination with gemcitabine and capecitabine in previously untreated metastatic/recurrent pancreatic cancer: Combined analysis with translational research.

: 4607 Background: To confirm the efficacy and toxicity of erlotinib (E) in combination with gemcitabine (G) and capecitabine (C) when used as a first-line therapy in patients (pts) with metastatic/recurrent pancreatic cancer Methods: Pts with advanced pancreatic adenocarcinoma, with measurable lesion were eligible for the study.

Locally advanced pancreatic cancer was excluded.

CONCLUSIONS: Erlotinib in combination with gemcitabine and capecitabine showed promising efficacy and good tolerability in metastatic pancreatic cancer.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 27964140.001).

[ISSN] 1527-7755

[Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology

[ISO-abbreviation] J. Clin. Oncol.

[Language] eng

[Publication-type] Journal Article

[Publication-country] United States

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] SPARC correlation with response to gemcitabine (G) plus nab-paclitaxel (nab-P) in patients with advanced metastatic pancreatic cancer: A phase I/II study.

: 4525 Background: Pancreatic cancer cells and surrounding stroma are known to overexpress SPARC (secreted protein acid rich in cysteine), which is associated with poor clinical outcomes. nab-P, an albumin-bound nanoparticle form of paclitaxel increased tumor accumulation of paclitaxel through binding of albumin to SPARC.

METHODS: nab-P doses (100-150 mg/m²) + (G) (1000 mg/m²) were given on days 1, 8, and 15 of a 28-day cycle to pts with metastatic pancreatic adenocarcinoma and with no prior chemotherapy for their metastatic disease.

CONCLUSIONS: The combination of nab-P and G was generally well tolerated and had substantial enough antitumor activity in patients with pancreatic cancer to warrant a phase III clinical trial.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 27962720.001).

[ISSN] 1527-7755

[Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology

[ISO-abbreviation] J. Clin. Oncol.

[Language] eng

[Publication-type] Journal Article

[Publication-country] United States

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Identification of chromosomal regions that harbor novel genes important for pancreatic cancer pathogenesis by genome-wide screening methods.

: e15609 Background: Pancreatic adenocarcinoma is a genetically highly complex and heterogenous tumor type with strong genetic instability which makes it resistant to therapy.

METHODS: We report the use of an Affymetrix Genome-Wide Human single nucleotide polymorphism (SNP) Array 6.0 (906,600 SNPs) to screen for gene copy number changes and allelic imbalances in 8 microdissected primary pancreatic tumors and 7 established pancreatic cancer cell lines.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 27962682.001).

[ISSN] 1527-7755

[Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology

[ISO-abbreviation] J. Clin. Oncol.

[Language] eng

[Publication-type] Journal Article

[Publication-country] United States

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Phase II study of gemcitabine chemotherapy alone for locally advanced pancreatic carcinoma: JCOG 0506.

: e15578 Background: Fluorouracil (5-FU) chemoradiotherapy has been accepted as standard care for locally advanced pancreatic cancer (LAPC); however, it has not been shown to be superior to chemotherapy alone in gemcitabine (Gem) era.

METHODS: Eligibility criteria included the following: patients (pts) with histologically or cytologically proven pancreatic adenocarcinoma or adenosquamous carcinoma, pts with UICC clinical stage III (T4N0-1 and M0), all lesions are assumed to be included in the radiation field of 15 cm square, age 20 or older, no prior treatment for LAPC, ECOG performance status of 0, 1 or 2, and adequate organ function.

Patient characteristics were: median age; 67.5 (45-80), male/female; 35/15, PS 0/1/2; 30/20/0, pancreatic head/body-tail; 26/24.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 27962370.001).

[ISSN] 1527-7755

[Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology

[ISO-abbreviation] J. Clin. Oncol.

[Language] eng

[Publication-type] Journal Article

[Publication-country] United States

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] A phase II study of radiation and docetaxel and cisplatin in the treatment of locally advanced pancreatic carcinoma. FNCLCC-ACCORD 09 /0201 trial.

: 4625 Background: Locally advanced pancreatic carcinoma remains a challenging tumor with no clear standard of care in terms of radio-chemotherapy.

The purpose of this phase II trial was to determine the efficacy and the toxicity of radiotherapy and docetaxel and cisplatin in histologically proven adenocarcinoma of the pancreas.

RESULTS: 51 pts (20 women and 31 men, with median age of 62 years) with disease considered to be unresectable but confined to pancreas area and celiac nodes were included between 06/10/2003 and 15/02/2008.

6 pts underwent secondary pancreatic resection (4 compete resection and 1 pt with histological complete remission).

CONCLUSIONS: The association docetaxel+cisplatin+radiotherapy has limited effect in patients with locally advanced pancreatic carcinoma but major objective responses have been observed allowing secondary resections.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 27964209.001).

[ISSN] 1527-7755

[Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology

[ISO-abbreviation] J. Clin. Oncol.

[Language] eng

[Publication-type] Journal Article

[Publication-country] United States

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Phase I radiation dose-escalation trial of intensity-modulated radiotherapy (IMRT) with concurrent fixed dose-rate gemcitabine (FDR-G) for unresectable pancreatic cancer.

: 4602 Background: Current treatments of non-metastatic, unresectable pancreatic cancer result in poor survival and nearly uniform local persistence of disease.

METHODS: Eligibility included tissue diagnosis of adenocarcinoma, unresectable by radiological criteria, Zubrod performance of 0-2, ANC of ≥ 1500/mm3, platelets ≥ 100,000/mm3, creatinine < 2 mg/dl, bilirubin < 3 mg/dl, ALT and AST ≤ 2.5 x ULN, and informed consent.

GTV was defined on pancreas protocol CT in the treatment position.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 27964152.001).

[ISSN] 1527-7755

[Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology

[ISO-abbreviation] J. Clin. Oncol.

[Language] eng

[Publication-type] Journal Article

[Publication-country] United States

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] A multicenter randomized phase II study of full-dose gemcitabine and concurrent radiotherapy comparing gemcitabine alone for the unresectable locally advanced pancreatic adenocarcinoma.

: e15512 Background: Some of locally advanced pancreatic cancers (LAPC) are considered to include a potential micro metastasis.

METHODS: Patients with histologically or cytologically proven pancreatic adenocarcinoma were eligible for this study.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 27962283.001).

[ISSN] 1527-7755

[Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology

[ISO-abbreviation] J. Clin. Oncol.

[Language] eng

[Publication-type] Journal Article

[Publication-country] United States

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Health-related quality of life and pain assessment in 36 patients with resected pancreas adenocarcinoma: Preliminary analysis.

: e20692 Background: In order to begin to understand the effects of disease on the patient (pt) and possibly of the pt on the disease, we have begun a systematic psychological inventory of all our pts who have has a pancreatectomy for pancreas adenocarcinoma and have began to correlate this with disease extent, and later with survival.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 27961756.001).

[ISSN] 1527-7755

[Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology

[ISO-abbreviation] J. Clin. Oncol.

[Language] eng

[Publication-type] Journal Article

[Publication-country] United States

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] A phase II study of Halichondrin B analog eribulin mesylate (E7389) as second-line therapy for patients with advanced pancreatic cancer.

Preclinical studies suggest that Eribulin may be effective in pancreatic cancer.

The primary objective of this study was to determine the objective response rate (complete and partial) to Eribulin in patients with advanced, pancreatic adenocarcinoma that had progressed after gemcitabine based therapy.

METHODS: Eligibility criteria included histologically confirmed pancreatic adenocarcinoma; measurable locally advanced, or metastatic disease; disease progression after gemcitabine; and ECOG performance status 0-2.

CONCLUSIONS: Eribulin was well tolerated and did not result in any objective responses in refractory pancreatic cancer.

Further studies of eribulin in pancreatic cancer may be warranted.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 27962741.001).

[ISSN] 1527-7755

[Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology

[ISO-abbreviation] J. Clin. Oncol.

[Language] eng

[Publication-type] Journal Article

[Publication-country] United States

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

RESULTS: 25 pts have been enrolled, including 21 with pancreatic adenocarcinoma, 3 of whom had received prior G. 21 pts were evaluable for toxicity and 18 for efficacy.

To address these toxicities, once daily dosing of D will be explored, followed by an expanded cohort of G + daily D vs G + bid D in pts with treatment-naïve pancreatic cancer.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 27962236.001).

[ISSN] 1527-7755

[Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology

[ISO-abbreviation] J. Clin. Oncol.

[Language] eng

[Publication-type] Journal Article

[Publication-country] United States

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Second-line pemetrexed-oxaliplatin combination for advanced pancreatic adenocarcinoma.

: e15597 Background: Few regimens showed efficacy in advanced pancreatic cancer patients (pts) who had failed a first-line gemcitabine-based therapy.

METHODS: Pancreatic cancer pts with advanced disease, PS>60, age>18 years, who progressed after a gemcitabine-based therapy were enrolled in a phase II trial, and treated with pemetrexed 500 mg/mq followed by oxaliplatin 120 mg/mq, day 1 every 3 weeks, together with adequate oral folinic acid and intramuscular vitamin B12 supplementation.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 27962879.001).

[ISSN] 1527-7755

[Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology

[ISO-abbreviation] J. Clin. Oncol.

[Language] eng

[Publication-type] Journal Article

[Publication-country] United States

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Phase II trial of neoadjuvant fixed dose rate (FDR) gemcitabine with capecitabine (GX) combination chemotherapy in locally advanced pancreatic adenocarcinoma (LAPA).

: e15553 Background: To determine the efficacy and safety of fixed dose rate (FDR) gemcitabine and capecitaibne (GX) combination chemotherapy for locally advanced pancreatic adenocarcinoma Methods: Patients with histologically confirmed LAPA were eligible for this prospective phase II trial.

Dynamic pancreas/pelvic CT, MRI and FDG-PET were undertaken to assess the resectability.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 27962334.001).

[ISSN] 1527-7755

[Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology

[ISO-abbreviation] J. Clin. Oncol.

[Language] eng

[Publication-type] Journal Article

[Publication-country] United States

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Use of a genome-wide association study to detect candidate polymorphisms associated with overall survival in stage IV pancreatic adenocarcinoma patients receiving gemcitabine monotherapy.

We performed a genome-wide association study (GWAS) in Japanese patients with stage IV pancreatic adenocarcinoma receiving gemcitabine (Gem) monotherapy.

METHODS: Metastatic pancreatic ductal adenocarcinoma patients who had previously received neither radiation nor chemotherapy were eligible in this study.

CONCLUSIONS: GWAS is a powerful tool to search for new prognostic biomarkers for patients with stage IV pancreatic adenocarcinoma receiving Gem monotherapy and may reveal as yet unexplored molecular pathways which correlate with drug response.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 27964191.001).

[ISSN] 1527-7755

[Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology

[ISO-abbreviation] J. Clin. Oncol.

[Language] eng

[Publication-type] Journal Article

[Publication-country] United States

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Soluble iC3b as an early marker for pancreatic adenocarcinoma compared to CA 19.9 and radiology.

: 4626 Background: Pancreatic adenocarcinoma as an aggressive tumor still lacks specific markers.

Resection offers the only potential cure, and earlier diagnosis could benefit many patients.

Complement regulatory proteins are highly expressed on pancreatic carcinoma cells and detectable in patient's urine.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 27964206.001).

[ISSN] 1527-7755

[Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology

[ISO-abbreviation] J. Clin. Oncol.

[Language] eng

[Publication-type] Journal Article

[Publication-country] United States

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

Cephalic pancreaticoduodenectomy is the best treatment for cephalic pancreas cancers.

We report the case of a 40 old woman who underwent cephalic pancreaticoduodenectomy for an adenocarcinoma of pancreas head.

This case report talks about the importance of angioscanner before pancreatic surgery when celiac and mesenteric angiography is not available.

[MeSH-major] Adenocarcinoma / surgery. Hepatic Artery. Ischemia / etiology. Pancreatic Neoplasms / surgery. Pancreaticoduodenectomy / adverse effects

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 16295763.001).

[ISSN] 0049-1101

[Journal-full-title] Dakar médical

[ISO-abbreviation] Dakar Med

[Language] fre

[Publication-type] Case Reports; English Abstract; Journal Article

[Publication-country] Senegal

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] [Mucinous noncystic (colloid) adenocarcinoma of the pancreas].

OBJECTIVE: To determine the clinicopathologic characteristics and the relationship between related gene expression and pathobiologic behavior of pancreatic mucinous noncystic adenocarcinoma.

METHODS: Among the 249 pancreatic carcinoma cases from the department files, 6 tumors were identified to meet the pathologic criteria of colloid carcinoma.

RESULTS: In all 6 cases, the tumors were located in the head of the pancreas and all displayed similar microscopic findings.

CONCLUSIONS: Pancreatic mucinous noncystic adenocarcinoma has distinct morphologic features and biologic behavior.

Multiple gene products including many cyclins may be involved in the pathogenesis of pancreatic colloid carcinoma.

The tumor has an aggressive behavior with a high frequency of invasion and metastases, though the prognosis could be better than that of ordinary ductal adenocarcinoma of pancreas.

[MeSH-major] Adenocarcinoma, Mucinous / pathology. Pancreatic Neoplasms / pathology

MedlinePlus Health Information. consumer health - Pancreatic Cancer.

NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 16251039.001).

[ISSN] 0529-5807

[Journal-full-title] Zhonghua bing li xue za zhi = Chinese journal of pathology

[ISO-abbreviation] Zhonghua Bing Li Xue Za Zhi

[Language] chi

[Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't

[Publication-country] China

[Chemical-registry-number] 0 / Cyclin-Dependent Kinase Inhibitor p16; EC 3.6.5.2 / Proto-Oncogene Proteins p21(ras)

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

Other histological findings were sinusoidal and centrivenular congestion in 14 (23.3%), extensive fatty change 6 (10%), portal inflammation resembling chronic hepatitis 5 (8.3%), focal necrosis 2 (3.3%), Kupffer cell hyperplasia 1 (1.6%) and metastasis from known case of adenocarcinoma of pancreas 1 (1.6%).

Genetic Alliance. consumer health - HIV.

MedlinePlus Health Information. consumer health - HIV/AIDS.

MedlinePlus Health Information. consumer health - HIV/AIDS in Women.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 15798661.001).

[ISSN] 1665-2681

[Journal-full-title] Annals of hepatology

[ISO-abbreviation] Ann Hepatol

[Language] eng

[Publication-type] Journal Article

[Publication-country] Mexico

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] [Solitary metachronous metastasis of the sternum from pancreatic adenocarcinoma].

[Transliterated title] Metastasi umica metacrona dello sterno da adenocarcinoma del pancreas.

Sternal metastases from adenocarcinoma of the pancreas are extremely rare, and even more so when solitary.

Two years earlier, the patient reported on here, a 67-year-old man with a solitary osteolytic lesion of the sternal manubrium, had undergone a duodeno-cephalopancreatectomy for adenocarcinoma of the pancreas (G2, pY3, pN1) followed by adjuvant radio-chemotherapy.

The histological examination revealed secondary adenocarcinoma with 3 mediastinal metastatic lymph nodes.

[MeSH-major] Adenocarcinoma / secondary. Bone Neoplasms / secondary. Bone Neoplasms / surgery. Pancreatic Neoplasms. Sternum

MedlinePlus Health Information. consumer health - Bone Cancer.

MedlinePlus Health Information. consumer health - Pancreatic Cancer.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 18361001.001).

[ISSN] 0009-4773

[Journal-full-title] Chirurgia italiana

[ISO-abbreviation] Chir Ital

[Language] ita

[Publication-type] Case Reports; English Abstract; Journal Article

[Publication-country] Italy

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] [Cerebellar metastasis from pancreatic adenocarcinoma: report of a clinical case].

[Transliterated title] Metastasi cerebellare da adenocarcinoma del pancreas descrizione di un caso clinico.

We describe a case of a metacronous cerebellar metastasis from pancreatic adenocarcinoma occurred in a 67 years old male.

Central nervous system metastases from pancreatic carcinoma are mostly autoptic findings.

To our knowledge, this is the first case reported in literature of cerebellar metastasis from pancreatic cancer; furthermore, this case calls attention on vomit presentation that could be erroneously attributed to an abdominal relapse.

[MeSH-major] Adenocarcinoma / secondary. Cerebellar Neoplasms / secondary. Pancreatic Neoplasms / pathology

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 16437906.001).

[ISSN] 2283-5423

[Journal-full-title] I supplementi di Tumori : official journal of Società italiana di cancerologia ... [et al.]

[ISO-abbreviation] Suppl Tumori

[Language] ita

[Publication-type] Case Reports; English Abstract; Journal Article

[Publication-country] Italy

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] [Pancreatic adenocarcinoma in young patient diagnosed by endoscopic ultrasonography].

[Transliterated title] Adenocarcinoma de páncreas en paciente joven diagnosticado por ultrasonografía endoscópica.

The Pancreatic adenocarcinoma appears generally in patients with more than 60 years old.

The tomografic image showed a mass located in the head of the pancreas with hepatic and ganglionar metastases.

It was evaluated by means of endoscopic ultrasonography (USE) and performed a directed fine needle puncture aspiration (PAAF), that obtained a bad differentiated adenocarcinoma from the pancreas.

We present the case by the unusual occurrence in the related age group and by the importance of the puncture guided by endoscopic ultrasonography in the diagnosis and handling of this pathology [corrected]

[MeSH-major] Adenocarcinoma / ultrasonography. Endosonography. Pancreatic Neoplasms / ultrasonography

[Email] Email this result item

Email the results to the following email address:   [X] Close

[ErratumIn] Rev Gastroenterol Peru. 2008 Jul-Sep;28(3):293

(PMID = 18641779.001).

[ISSN] 1022-5129

[Journal-full-title] Revista de gastroenterología del Perú : órgano oficial de la Sociedad de Gastroenterología del Perú

[ISO-abbreviation] Rev Gastroenterol Peru

[Language] spa

[Publication-type] Case Reports; English Abstract; Journal Article

[Publication-country] Peru

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] [Groove pancreatitis and its differential diagnosis with pancreatic adenocarcinoma].

[Transliterated title] Pancreatitis del surco y su diagnóstico diferencial con el adenocarcinoma de páncreas.

We analyzed the clinical, radiographic and histologic characteristics, as well as the difficulties that arose in the differential diagnosis between groove pancreatitis (a benign entity consisting of a segmental form of chronic pancreatitis occurring as a sheet-like scar in the area of pancreatoduodenal groove) and adenocarcinoma of the pancreas.

To this end, four cases with abnormalities in the groove area were retrospectively reviewed, three with groove pancreatitis, and one with adenocarcinoma of the pancreas.

The important role of imaging techniques is highlighted, with emphasis on magnetic resonance imaging of the pancreas and magnetic resonance cholangiography, which reveal certain differentiating characteristics between these two entities.

[MeSH-major] Adenocarcinoma / diagnosis. Duodenitis / diagnosis. Pancreatic Neoplasms / diagnosis. Pancreatitis / diagnosis

[MeSH-minor] Adult. Aged. Biopsy, Fine-Needle. Cholangiopancreatography, Endoscopic Retrograde. Cholangiopancreatography, Magnetic Resonance. Cholelithiasis / complications. Cholelithiasis / diagnosis. Chronic Disease. Diagnosis, Differential. Duodenum / pathology. Fatal Outcome. Humans. Intestinal Mucosa / pathology. Magnetic Resonance Imaging. Male. Middle Aged. Pancreaticoduodenectomy. Pancreatitis, Alcoholic / complications. Retrospective Studies

Genetic Alliance. consumer health - Pancreatitis.

MedlinePlus Health Information. consumer health - Pancreatic Cancer.

[Email] Email this result item

Email the results to the following email address:   [X] Close

[CommentIn] Gastroenterol Hepatol. 2009 Nov;32(9):662-3 [19525034.001]

(PMID = 19174095.001).

[ISSN] 0210-5705

[Journal-full-title] Gastroenterología y hepatología

[ISO-abbreviation] Gastroenterol Hepatol

[Language] spa

[Publication-type] Case Reports; English Abstract; Journal Article

[Publication-country] Spain

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] [Surgical treatment of pancreatic adenocarcinoma using cephalic duodenopancreatectomy (Part 2). Long term follow up after 204 cases].

[Transliterated title] Tratamiento quirúrgico del adenocarcinoma pancreático mediante duodenopancreatectomía cefálica (parte 2). Seguimiento a largo plazo tras 204 casos.

INTRODUCTION: Surgery is the accepted treatment in adenocarcinoma of the head of the pancreas; however, the long-term survival continues to be low.

The aim of this study is to define prognostic factors of long-term survival after cephalic duodenopancreatectomy due to pancreatic adenocarcinoma.

MATERIAL AND METHODS: We have collected data on the treatment of adenocarcinoma of the head of the pancreas (ADHP) by means of a cephalic duodenopancreatectomy (CDP) performed n the Bellvitge University Hospital (Barcelona) from 1991 to 2007.

CONCLUSIONS: Surgery of head of the pancreas adenocarcinoma must include an adequate lymphadectomy, and must be performed with a low morbidity and without the need of a peri-operative transfusion.

[MeSH-major] Adenocarcinoma / surgery. Pancreatic Neoplasms / surgery. Pancreaticoduodenectomy

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Copyright] Copyright © 2010 AEC. Published by Elsevier Espana. All rights reserved.

[CommentIn] Cir Esp. 2011 Jun-Jul;89(6):411; author reply 412 [21550599.001]

(PMID = 21030012.001).

[ISSN] 1578-147X

[Journal-full-title] Cirugía española

[ISO-abbreviation] Cir Esp

[Language] spa

[Publication-type] English Abstract; Journal Article

[Publication-country] Spain

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] [Pancreatic adenocarcinoma: therapeutical update].

[Transliterated title] Adenocarcinoma de páncreas: actualizaciones terapéuticas.

Cancer of the exocrine pancreas continues to be a major unsolved health problem.

Because of difficulties in diagnosis, the aggressiveness of pancreatic cancers, and the lack of effective systemic therapies, generally fewer than 5% of patients with adenocarcinoma of the pancreas survive 5 years after diagnosis.

The median survival in metastatic pancreatic cancer is nearly six months.Today, surgery remains the only curative therapeutic option, and the standard treatment in patients with advanced disease is gemcitabine.

New strategies for resectable and unresectable pancreatic cancer are under active investigation,such as neoadjuvant or adjuvant chemoradiotherapy or combinations of gemcitabine with new cytotoxic agents (oxaliplatin, cetuximab, gefitinib, bevacizumab) with promising results.

In patients with locally advanced pancreatic cancer and good performance status, chemoradiotherapy should be considered.

[MeSH-major] Adenocarcinoma / therapy. Pancreatic Neoplasms / therapy

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 16351494.001).

[ISSN] 0212-7199

[Journal-full-title] Anales de medicina interna (Madrid, Spain : 1984)

[ISO-abbreviation] An Med Interna

[Language] spa

[Publication-type] English Abstract; Journal Article; Review

[Publication-country] Spain

[Number-of-references] 37

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] [Surgical treatment of pancreatic adenocarcinoma by cephalic duodenopancreatectomy (Part 1). Post-surgical complications in 204 cases in a reference hospital].

[Transliterated title] Tratamiento quirúrgico del adenocarcinoma pancreático mediante duodenopancreatectomía cefálica (Parte 1). Complicaciones postoperatorias en 204 casos en un centro de referencia.

INTRODUCTION: Cephalic duodenopancreatectomy (CDP) is the treatment of choice in cancer of the head of the pancreas.

The aim of this article is to define variables that influence post-surgical morbidity and mortality after cephalic duodenopancreatectomy due to pancreatic adenocarcinoma (PA) cancer of the head of the pancreas (CHP).

Post-surgical complications were detected in 45% of cases, the most frequent being: slow gastric emptying (20%), surgical wound infection (17%), pancreatic fistula (10%), and serious medical complications (8%).

Pancreatic fistula was not a factor associated with post-surgical mortality.

[MeSH-major] Adenocarcinoma / surgery. Duodenum / surgery. Pancreatectomy / methods. Pancreatic Neoplasms / surgery

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Copyright] Copyright © 2010 AEC. Published by Elsevier Espana. All rights reserved.

(PMID = 20663494.001).

[ISSN] 1578-147X

[Journal-full-title] Cirugía española

[ISO-abbreviation] Cir Esp

[Language] spa

[Publication-type] English Abstract; Journal Article

[Publication-country] Spain

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Targeted therapies for pancreatic adenocarcinoma.

The majority of patients diagnosed with adenocarcinoma of the pancreas have advanced disease at presentation, with only 20% surviving beyond one year.

Systemic therapy for pancreatic adenocarcinoma to date has failed to provide more than a very modest survival benefit for patients with advanced disease.

However, the past decade has seen significant advances in the understanding of the molecular pathogenesis of pancreatic cancer, culminating in the sequencing of the pancreatic cancer genome.

New generations of therapeutic agents targeting key oncogenic cellular signaling pathways are currently under evaluation in advanced pancreatic adenocarcinoma.

Herein the authors review the evidence to date for the use of novel cytotoxic and molecularly targeted agents in pancreatic adenocarcinoma, and discuss key areas for future therapeutic development.

[MeSH-major] Adenocarcinoma / drug therapy. Pancreatic Neoplasms / drug therapy. ras Proteins / antagonists & inhibitors

MedlinePlus Health Information. consumer health - Pancreatic Cancer.

NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 19859040.001).

[ISSN] 0026-4733

[Journal-full-title] Minerva chirurgica

[ISO-abbreviation] Minerva Chir

[Language] eng

[Publication-type] Journal Article; Review

[Publication-country] Italy

[Chemical-registry-number] 0 / Vascular Endothelial Growth Factor A; EC 2.7.10.1 / EGFR protein, human; EC 2.7.10.1 / Receptor, Epidermal Growth Factor; EC 2.7.10.1 / Receptor, IGF Type 1; EC 2.7.10.1 / Receptors, Platelet-Derived Growth Factor; EC 2.7.10.2 / src-Family Kinases; EC 3.6.5.2 / ras Proteins

[Number-of-references] 127

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Arterial variants in pancreatic adenocarcinoma.

Surgery remains the only curative option for the treatment of pancreatic adenocarcinoma.

Unexpected variant arterial anatomy or tumor involvement of aberrant arteries may complicate pancreatic surgery.

We describe here the arterial variant anatomy of the pancreas and its identification by multidetector CT imaging, with and without the aid of post-processed volume-rendered images.

[MeSH-major] Adenocarcinoma / blood supply. Celiac Artery / abnormalities. Mesenteric Arteries / abnormalities. Pancreas / blood supply. Pancreatic Neoplasms / blood supply

MedlinePlus Health Information. consumer health - Pancreatic Cancer.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 17435979.001).

[ISSN] 1432-0509

[Journal-full-title] Abdominal imaging

[ISO-abbreviation] Abdom Imaging

[Language] eng

[Publication-type] Journal Article; Review

[Publication-country] United States

[Chemical-registry-number] 0 / Contrast Media

[Number-of-references] 22

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Staging of pancreatic adenocarcinoma by imaging studies.

Imaging studies play a crucial role in the diagnosis and management of patients with pancreatic adenocarcinoma.

Computed tomography (CT) is the most widely available and best-validated modality for imaging patients with pancreatic adenocarcinoma.

To maximize the diagnostic efficacy of CT, use of a pancreas protocol is mandatory.

The sensitivity of CT for diagnosis of pancreatic adenocarcinoma (89%-97%) and its positive predictive value for predicting unresectability (89%-100%) are high.

Magnetic resonance imaging has not been shown to perform better than CT for the diagnosis and staging of pancreatic adenocarcinoma, but can be helpful as an adjunct to CT, particularly for evaluation of small hepatic lesions that cannot be fully characterized by CT.

Ultrasound is often the first study obtained in patients with obstructive jaundice or unexplained abdominal pain, but its utility for diagnosis and staging of patients with pancreatic adenocarcinoma is limited.

Positron emission tomography/CT combines the functional information provided by positron emission tomography with the anatomic information provided by CT and is a promising modality for imaging of patients with pancreatic adenocarcinoma, but its utility has not been established.

Endoscopic ultrasound is generally considered superior to CT for the diagnosis and local staging of pancreatic cancer, but is limited by availability and inability to assess for distant metastases.

[MeSH-major] Adenocarcinoma / diagnosis. Adenocarcinoma / pathology. Pancreas / radiography. Pancreas / ultrasonography. Pancreatic Neoplasms / diagnosis. Pancreatic Neoplasms / pathology. Severity of Illness Index

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 18948228.001).

[ISSN] 1542-7714

[Journal-full-title] Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association

[ISO-abbreviation] Clin. Gastroenterol. Hepatol.

[Language] eng

[Publication-type] Journal Article; Review

[Publication-country] United States

[Number-of-references] 42

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Proteomic analysis of chronic pancreatitis and pancreatic adenocarcinoma.

BACKGROUND & AIMS: Markers to differentiate among pancreatic adenocarcinoma, chronic pancreatitis, and normal pancreas would be of significant clinical utility.

This study was therefore designed to analyze the proteome of such specimens and identify new candidate proteins for differential diagnosis.

METHODS: A PowerBlot analysis with more than 900 well-characterized antibodies was performed with tissue specimens from patients with chronic pancreatitis, pancreatic adenocarcinoma, and normal pancreas.

RESULTS: A total of 30 and 102 proteins showed significant deregulation between normal pancreas when compared with chronic pancreatitis and pancreatic adenocarcinoma, respectively, and although a substantial proportion were found similarly dysregulated in both chronic pancreatitis and pancreatic adenocarcinoma, several proteins were identified as potential disease-specific markers.

CONCLUSIONS: A large number of proteins are differentially expressed in chronic pancreatitis and pancreatic adenocarcinoma compared with normal pancreas.

[MeSH-major] Adenocarcinoma / physiopathology. Pancreatic Neoplasms / physiopathology. Pancreatitis, Chronic / physiopathology. Protein Array Analysis. Proteomics

Genetic Alliance. consumer health - Pancreatitis.

MedlinePlus Health Information. consumer health - Pancreatic Cancer.

COS Scholar Universe. author profiles.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 16285947.001).

[ISSN] 0016-5085

[Journal-full-title] Gastroenterology

[ISO-abbreviation] Gastroenterology

[Language] eng

[Publication-type] Journal Article; Research Support, Non-U.S. Gov't

[Publication-country] United States

[Chemical-registry-number] 0 / Biomarkers, Tumor

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Discovery and analysis of pancreatic adenocarcinoma genes using cDNA microarrays.

AIM: To study the pathogenetic processes and the role of gene expression by microarray analyses in expediting our understanding of the molecular pathophysiology of pancreatic adenocarcinoma, and to identify the novel cancer-associated genes.

METHODS: Nine histologically defined pancreatic head adenocarcinoma specimens associated with clinical data were studied.

In pancreatic adenocarcinoma tissue, several invasion and metastasis related genes showed their high expression levels, suggesting that poor prognosis of pancreatic adenocarcinoma might have a solid molecular biological basis.

CONCLUSION: The application of cDNA microarray technique for analysis of gene expression patterns is a powerful strategy to identify novel cancer-associated genes, and to rapidly explore their role in clinical pancreatic adenocarcinoma.

Microarray profiles provide us new insights into the carcinogenesis and invasive process of pancreatic adenocarcinoma.

Our results suggest that a highly organized and structured process of tumor invasion exists in the pancreas.

[MeSH-major] Adenocarcinoma / genetics. Gene Expression Profiling / methods. Gene Expression Regulation, Neoplastic. Oligonucleotide Array Sequence Analysis / methods. Pancreatic Neoplasms / genetics

MedlinePlus Health Information. consumer health - Pancreatic Cancer.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 16425432.001).

[ISSN] 1007-9327

[Journal-full-title] World journal of gastroenterology

[ISO-abbreviation] World J. Gastroenterol.

[Language] eng

[Publication-type] Journal Article; Research Support, Non-U.S. Gov't

[Publication-country] China

[Other-IDs] NLM/ PMC4355802

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Oligonucleotide-directed microarray gene profiling of pancreatic adenocarcinoma.

In this chapter we describe our approach to the profiling of pancreatic adenocarcinoma to illustrate the various steps and methods involved in this type of study.

Pancreatic adenocarcinoma is a particularly challenging subject for gene profiling, as these tumors have a profound desmoplastic response such that neoplastic epithelium makes up only a small proportion of the tissue mass.

We have utilized statistical comparisons of gene expression between adenocarcinoma, normal pancreas, samples of chronic pancreatitis, and pancreatic cancer cell lines that provides a means to deduct the influence of the stromal elements.

[MeSH-major] Adenocarcinoma / genetics. Gene Expression Profiling / methods. Oligonucleotide Array Sequence Analysis / methods. Pancreatic Neoplasms / genetics

MedlinePlus Health Information. consumer health - Pancreatic Cancer.

COS Scholar Universe. author profiles.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 15542906.001).

[ISSN] 1543-1894

[Journal-full-title] Methods in molecular medicine

[ISO-abbreviation] Methods Mol. Med.

[Language] eng

[Publication-type] Journal Article

[Publication-country] United States

[Chemical-registry-number] 0 / Oligodeoxyribonucleotides

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Is resection of periampullary or pancreatic adenocarcinoma with synchronous hepatic metastasis justified?

Specifically, the role of hepatic resection for metastatic periampullary or pancreatic adenocarcinoma remains controversial.

METHODS: Between 1995 and 2005, 1563 patients underwent surgical resection for periampullary carcinoma (n=608 patients) or pancreatic adenocarcinoma (head, n=905 patients; tail, n=50 patients).

RESULTS: Of the 1563 patients who underwent resection of periampullary or pancreatic adenocarcinoma, 22 patients (1.4%) underwent simultaneous hepatic resection for synchronous liver metastasis.

The primary tumor site was ampullary (n=1 patient ), duodenal (n=2 patients), distal bile duct (n=2 patients), or pancreas (head, n=10 patients; tail, n=7 patients).

Pancreatic (median, 5.9 months) versus nonpancreatic (median, 9.9 months) primary tumor histology was not associated with a difference in survival in patients who underwent resection of synchronous liver metastasis (P=.43).

CONCLUSIONS: Even in well selected patients with low-volume metastatic liver disease, simultaneous resection of periampullary or pancreatic carcinoma with synchronous liver metastases did not result in long-term survival in the overwhelming majority of patients.

[MeSH-major] Adenocarcinoma / surgery. Liver Neoplasms / secondary. Pancreatic Neoplasms / surgery. Pancreaticoduodenectomy

MedlinePlus Health Information. consumer health - Liver Cancer.

MedlinePlus Health Information. consumer health - Pancreatic Cancer.

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Copyright] Copyright (c) 2007 American Cancer Society.

(PMID = 17941009.001).

[ISSN] 0008-543X

[Journal-full-title] Cancer

[ISO-abbreviation] Cancer

[Language] eng

[Publication-type] Journal Article; Research Support, Non-U.S. Gov't

[Publication-country] United States

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Small undifferentiated pancreatic adenocarcinoma which mimics IPMN at imaging.

CONTEXT: To present the case of an unusual presentation at imaging of a very small solid undifferentiated pancreatic adenocarcinoma which mimics a side-branch intraductal papillary mucinous neoplasm.

CASE REPORT: The patient came to our hospital for a revaluation of a cystic pancreatic lesion.

A small cystic lesion of about 1.5 cm in diameter was seen in the posterior aspect of the pancreatic uncinate process A very small, solid, vascularized nodule was detected at CEUS within the lesion.

MRI confirmed the presence of an intralesional nodule and communication with the main pancreatic duct was demonstrated, suggesting the diagnosis of intraductal papillary mucinous neoplasm with solid intralesional tissue.

An undifferentiated adenocarcinoma having a notable peripheral inflammatory reaction and dilated branch duct was finally diagnosed.

CONCLUSION: To our knowledge, we present for the first time, the case of a very small solid undifferentiated pancreatic adenocarcinoma of the uncinate process which mimicked a side-branch intraductal papillary mucinous neoplasm at imaging.

[MeSH-major] Adenocarcinoma / diagnosis. Adenocarcinoma, Mucinous / diagnosis. Carcinoma, Pancreatic Ductal / diagnosis. Carcinoma, Papillary / diagnosis. Pancreatic Neoplasms / diagnosis

[MeSH-minor] Diagnosis, Differential. Female. Humans. Magnetic Resonance Imaging. Middle Aged

MedlinePlus Health Information. consumer health - Pancreatic Cancer.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 19581744.001).

[ISSN] 1590-8577

[Journal-full-title] JOP : Journal of the pancreas

[ISO-abbreviation] JOP

[Language] eng

[Publication-type] Case Reports; Journal Article

[Publication-country] Italy

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] MRI of adenocarcinoma of the pancreas.

OBJECTIVE: CT is the established imaging technique for evaluation of pancreatic adenocarcinoma.

The objective of this study is to illustrate the strengths of MRI for evaluating pancreatic adenocarcinoma.

CONCLUSION: The superior soft-tissue contrast of MRI compared with CT is useful in the detection and characterization of non-contour-deforming pancreatic masses.

[MeSH-major] Adenocarcinoma / diagnosis. Magnetic Resonance Imaging. Pancreatic Neoplasms / diagnosis

[MeSH-minor] Adult. Carcinoma, Pancreatic Ductal / diagnosis. Carcinoma, Pancreatic Ductal / radiography. Diagnosis, Differential. Humans. Liver Neoplasms / radiography. Liver Neoplasms / secondary. Lymphatic Metastasis. Male. Middle Aged. Pancreatitis / diagnosis. Tomography, X-Ray Computed

MedlinePlus Health Information. consumer health - MRI Scans.

MedlinePlus Health Information. consumer health - Pancreatic Cancer.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 16985107.001).

[ISSN] 1546-3141

[Journal-full-title] AJR. American journal of roentgenology

[ISO-abbreviation] AJR Am J Roentgenol

[Language] eng

[Publication-type] Journal Article

[Publication-country] United States

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Discovery of serum biomarkers for pancreatic adenocarcinoma using proteomic analysis.

BACKGROUND AND AIMS: The serum/plasma proteome was explored for biomarkers to improve the diagnostic ability of CA19-9 in pancreatic adenocarcinoma (PC).

[MeSH-major] Adenocarcinoma / blood. Apolipoprotein A-I / blood. Apolipoprotein C-I / blood. Biomarkers, Tumor / blood. CA-19-9 Antigen / blood. Carcinoma, Pancreatic Ductal / blood. Proteomics / methods

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Cites] Ann Surg Oncol. 2008 Dec;15(12):3512-20 [18781364.001]

[Cites] Int J Cancer. 2008 Dec 15;123(12):2880-4 [18803289.001]

[Cites] J Clin Oncol. 2008 Dec 20;26(36):5918-22 [19029412.001]

[Cites] World J Surg. 2009 Apr;33(4):716-22 [19082654.001]

[Cites] J Mol Biol. 2009 Apr 3;387(3):628-38 [19236880.001]

[Cites] Eur J Surg Oncol. 2009 Jun;35(6):605-10 [19128923.001]

[Cites] Int J Biochem Cell Biol. 2009 Aug-Sep;41(8-9):1731-8 [19433314.001]

[Cites] Clin Chem Lab Med. 2009;47(6):713-23 [19426140.001]

[Cites] Metabolism. 2009 Aug;58(8):1131-6 [19493551.001]

[Cites] Clin Sci (Lond). 2010 Jan;118(1):79-85 [19456294.001]

[Cites] Clin Chem Lab Med. 2009;47(11):1389-94 [19817643.001]

[Cites] Cancer Sci. 2009 Dec;100(12):2292-301 [19775290.001]

[Cites] Med Sci Monit. 2000 Mar-Apr;6(2):325-9 [11208331.001]

[Cites] J Lipid Res. 2001 Nov;42(11):1727-39 [11714842.001]

[Cites] Proc Natl Acad Sci U S A. 2002 May 14;99(10):6562-6 [11983868.001]

[Cites] Electrophoresis. 2002 Sep;23(17):3048-61 [12207315.001]

[Cites] Proteomics. 2003 Mar;3(3):243-8 [12627376.001]

[Cites] Ann Emerg Med. 2003 Aug;42(2):292-7 [12883521.001]

[Cites] J Gastroenterol Hepatol. 2004 Feb;19(2):182-6 [14731128.001]

[Cites] Clin Cancer Res. 2004 Feb 1;10(3):860-8 [14871961.001]

[Cites] Cancer Res. 2004 Apr 1;64(7):2397-405 [15059891.001]

[Cites] Radiology. 1983 Sep;148(3):839-43 [6878708.001]

[Cites] Biochim Biophys Acta. 1995 Jul 13;1257(2):174-80 [7619858.001]

[Cites] J Lipid Res. 1999 Mar;40(3):543-55 [10064743.001]

[Cites] Neoplasia. 2004 Sep-Oct;6(5):674-86 [15548376.001]

[Cites] Biochemistry. 2005 Jan 18;44(2):471-9 [15641771.001]

[Cites] Clin Cancer Res. 2005 Feb 1;11(3):1073-85 [15709174.001]

[Cites] Oncology. 2005;68(1):79-86 [15864000.001]

[Cites] Electrophoresis. 2005 Jul;26(14):2823-34 [15934056.001]

[Cites] Clin Chem. 2005 Sep;51(9):1637-49 [16002455.001]

[Cites] Cancer Biol Ther. 2005 Mar;4(3):302-7 [15876873.001]

[Cites] Cancer Res. 2005 Nov 15;65(22):10613-22 [16288055.001]

[Cites] Oncogene. 2006 Feb 16;25(7):981-9 [16186794.001]

[Cites] Gastroenterology. 2006 May;130(6):1670-8 [16697731.001]

[Cites] Pancreas. 2007 Mar;34(2):205-14 [17312459.001]

[Cites] Eur J Surg Oncol. 2007 Apr;33(3):266-70 [17097848.001]

[Cites] Curr Opin Gastroenterol. 2007 Sep;23(5):508-14 [17762556.001]

[Cites] Pancreas. 2008 Jan;36(1):61-9 [18192883.001]

[Cites] Oncogene. 2008 May 1;27(20):2810-22 [18037960.001]

(PMID = 20588270.001).

[ISSN] 1532-1827

[Journal-full-title] British journal of cancer

[ISO-abbreviation] Br. J. Cancer

[Language] eng

[Publication-type] Journal Article; Research Support, Non-U.S. Gov't

[Publication-country] England

[Chemical-registry-number] 0 / Apolipoprotein A-I; 0 / Apolipoprotein C-I; 0 / Biomarkers, Tumor; 0 / CA-19-9 Antigen; 0 / Protein Isoforms; EC 2.6.1.1 / Aspartate Aminotransferases; EC 2.6.1.2 / Alanine Transaminase

[Other-IDs] NLM/ PMC2920018

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] CD117/KIT expression in pancreatic adenocarcinoma.

Pancreatic adenocarcinoma has a poor prognosis, and therefore, targeted molecular therapy may be beneficial.

Marked differences in the incidence of CD117/KIT expression have been reported in pancreatic adenocarcinoma.

The aim of this study was to test the hypothesis that CD117/KIT expression is unusual in pancreatic adenocarcinoma.

METHODS: CD117/KIT immunohistochemistry was performed on 23 archival pancreatic adenocarcinoma samples using 2 primary antibodies.

However, CD117/KIT expression was also identified using the latter within nuclei and benign pancreatic epithelium, suggesting that artifactual staining was occurring.

CONCLUSIONS: Pancreatic adenocarcinoma does not express CD117/KIT as assessed using the primary immunohistochemical antibody usually used in our laboratory for CD117/KIT detection.

The variation in reported incidence of CD117/KIT expression in pancreatic adenocarcinoma is because of methodological differences in immunohistochemical technique.

[MeSH-major] Adenocarcinoma / chemistry. Pancreatic Neoplasms / chemistry. Proto-Oncogene Proteins c-kit / analysis

MedlinePlus Health Information. consumer health - Pancreatic Cancer.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 18192885.001).

[ISSN] 1536-4828

[Journal-full-title] Pancreas

[ISO-abbreviation] Pancreas

[Language] eng

[Publication-type] Journal Article; Research Support, Non-U.S. Gov't

[Publication-country] United States

[Chemical-registry-number] EC 2.7.10.1 / Proto-Oncogene Proteins c-kit

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Lysosomal exoglycosidases in serum and urine of patients with pancreatic adenocarcinoma.

The aim of the present paper was evaluation the activity of HEX, GAL, FUC and MAN in serum and urine of patients with pancreatic adenocarcinoma.

Serum and urine samples were collected from 15 patients with adenocarcinoma of the pancreas and 15 healthy persons.

The activity of lysosomal exoglycosidases was determined by the method of Marciniak et al. adapted to serum and urine of patients with adenocarcinoma of the pancreas.

Our results indicate significant decrease in activity of GAL (p=0.037) in serum of patients with pancreatic adenocarcinoma, significant increase in activity of HEX (p<0.001) and FUC (p=0.027) in serum, and HEX (p=0.003) in urine, as well as significant decrease of FUC (p=0.016) and MAN (p=0.029) in urine o patients with adenocarcinoma of the pancreas, in comparison to the control group.

Increase in activity of some lysosomal enzymes in serum and urine of pancreatic adenocarcinoma patients, may indicate on destruction of pancreatic tissue by pancreatic adenocarcinoma.

Determination of the HEX, GAL, FUC and MAN in serum and urine may be useful in diagnostics of pancreatic adenocarcinoma.

MedlinePlus Health Information. consumer health - Pancreatic Cancer.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 21071338.001).

[ISSN] 1897-5631

[Journal-full-title] Folia histochemica et cytobiologica

[ISO-abbreviation] Folia Histochem. Cytobiol.

[Language] ENG

[Publication-type] Comparative Study; Evaluation Studies; Journal Article

[Publication-country] Poland

[Chemical-registry-number] 0 / Glycoconjugates; EC 3.2.1.- / Glycoside Hydrolases; EC 3.2.1.23 / beta-Galactosidase; EC 3.2.1.24 / alpha-Mannosidase; EC 3.2.1.51 / alpha-L-Fucosidase; EC 3.2.1.52 / beta-N-Acetylhexosaminidases

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Immunosurveillance of pancreatic adenocarcinoma: insights from genetically engineered mouse models of cancer.

This is an especially important issue in pancreatic cancer, which although inflammatory in vivo is nevertheless highly aggressive and nearly always lethal.

Here, we review emerging data obtained from novel genetically defined mouse models of pancreatic adenocarcinoma that suggest that the immune system may be complicit in the inception and progression of pancreatic cancer.

Host immune cells with suppressive properties infiltrate the pancreas early during tumorigenesis, even at the earliest stages of neoplasia, preceding and effectively undermining any lymphocytes with potential antitumor function.

Thus, in pancreatic adenocarcinoma, the failure of immunosurveillance is likely an early event during tumorigenesis, a concept that carries important implications for the design of novel immunotherapeutics in this disease.

[MeSH-major] Adenocarcinoma / immunology. Neoplasms, Experimental / immunology. Pancreatic Neoplasms / immunology. Tumor Escape

MedlinePlus Health Information. consumer health - Pancreatic Cancer.

COS Scholar Universe. author profiles.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 19013709.001).

[ISSN] 1872-7980

[Journal-full-title] Cancer letters

[ISO-abbreviation] Cancer Lett.

[Language] eng

[Publication-type] Journal Article; Review

[Publication-country] Ireland

[Chemical-registry-number] EC 2.7.7.- / Cre recombinase; EC 2.7.7.- / Integrases; EC 3.6.5.2 / Kras2 protein, mouse; EC 3.6.5.2 / Proto-Oncogene Proteins p21(ras)

[Number-of-references] 70

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] [Pancreaticoduodenectomy for adenocarcinoma of the pancreatic head and papilla of Vater].

[Transliterated title] Duodenocefalopancreatectomia per adenocarcinoma della testa del pancreas e della papilla di Vater.

AIM: The authors report their consecutive experience in the surgical management of adenocarcinoma (ADC) of head of pancreas and papilla of Vater, in order to review the available literature.

METHODS: One hundred and seventy cases (131 in the head of pancreas and 39 in the papilla of Vater) were operated upon for ADC by radical pancreaticoduodenectomy in the period 1972-2005.

RESULTS: Postoperative morbidity was reported in 66 patients (38.8%) and pancreatic fistulae were observed in 39 patients (22.9%).

Five-year survival for pancreatic ADC was 75% in stage IA, 43.9% in stage IB and IIA, 3.2% in stage IIB.

The Wirsung duct has to be anastomosed directly to the jejunum and the pancreatic section needs to be checked.

[MeSH-major] Adenocarcinoma / surgery. Ampulla of Vater. Common Bile Duct Neoplasms / surgery. Neoplasms, Multiple Primary / surgery. Pancreatic Neoplasms / surgery. Pancreaticoduodenectomy

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 19648859.001).

[ISSN] 0026-4733

[Journal-full-title] Minerva chirurgica

[ISO-abbreviation] Minerva Chir

[Language] ita

[Publication-type] English Abstract; Journal Article; Review

[Publication-country] Italy

[Number-of-references] 79

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Radiology of pancreatic adenocarcinoma: current status of imaging.

Pancreatic adenocarcinoma is one of the leading causes of cancer death in the West, with a poor overall 5-year survival rate of only 4%.

Tumor serum marker CA 19-9 is sensitive, although not specific for the diagnosis of adenocarcinomas of the pancreas.

Many modalities are available to image the pancreas.

[MeSH-major] Adenocarcinoma / diagnosis. Pancreas / pathology. Pancreatic Neoplasms / diagnosis

MedlinePlus Health Information. consumer health - Pancreatic Cancer.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 18171340.001).

[ISSN] 1440-1746

[Journal-full-title] Journal of gastroenterology and hepatology

[ISO-abbreviation] J. Gastroenterol. Hepatol.

[Language] eng

[Publication-type] Journal Article; Review

[Publication-country] Australia

[Number-of-references] 66

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Laparoscopic distal pancreatectomy with preservation of the spleen and splenic vessels for pancreatic adenocarcinoma.

A computed tomography scan demonstrated a 4cm×5cm×5cm solid space-occupying mass in the distal pancreas.

The patient was referred to minimally invasive surgery service for resection of the pancreatic lesion.

RESULTS: The mass was completely excised, the pathological examination revealed grade II pancreatic adenocarcinoma.

Laparoscopic distal pancreatectomy with preservation of the spleen and splenic vessels for pancreatic adenocarcinoma.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 22666667.001).

[ISSN] 2250-1541

[Journal-full-title] North American journal of medical sciences

[ISO-abbreviation] N Am J Med Sci

[Language] eng

[Publication-type] Journal Article

[Publication-country] India

[Other-IDs] NLM/ PMC3364626

[Keywords] NOTNLM ; Laparoscopy / adenocarcinoma / distal pancreatectomy / laparoscopic spleen-preserving / pancreas / pancreatectomy / pancreatic cancer / space-occupying / splenic vessels

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] HFE genotypes in patients with chronic pancreatitis and pancreatic adenocarcinoma.

PURPOSE: The homozygous p.C282Y variant of the HFE gene is a major risk factor for hereditary hemochromatosis, a disorder of iron metabolism resulting in progressive iron accumulation in a variety of organs including the pancreas.

Heterozygosity of p.C282Y and p.H63D may increase susceptibility to chronic liver and pancreatic disease.

This study determines the frequencies of p.C282Y and p.H63D alterations in patients with chronic pancreatitis and pancreatic adenocarcinoma.

METHODS: In total, 958 patients (349 with alcoholic pancreatitis, 343 with idiopathic pancreatitis, 64 with familial chronic pancreatitis, 34 with acute pancreatitis, and 168 with pancreatic adenocarcinoma) were enrolled and compared with 681 healthy and 100 alcoholic controls.

RESULTS: No significant differences were found in heterozygosity for p.C282Y and p.H63D when patients with alcoholic (8.0/21.5%), idiopathic (7.3/24.5%), or familial (9.8/23.0%) pancreatitis, or pancreatic adenocarcinoma (5.4/28.6%) were compared with healthy (6.2/24.8%) and alcoholic (7.0/25.0%) controls.

CONCLUSION: Although hemochromatosis is associated with pancreatic pathology, the p.C282Y and p.H63D variants do not play a significant role in the pathogenesis of chronic pancreatitis or pancreatic adenocarcinoma.

[MeSH-major] Adenocarcinoma / genetics. Histocompatibility Antigens Class I / genetics. Membrane Proteins / genetics. Pancreatic Neoplasms / genetics. Pancreatitis, Chronic / genetics. Polymorphism, Restriction Fragment Length

Genetic Alliance. consumer health - Pancreatitis.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 17666895.001).

[ISSN] 1098-3600

[Journal-full-title] Genetics in medicine : official journal of the American College of Medical Genetics

[ISO-abbreviation] Genet. Med.

[Language] eng

[Publication-type] Clinical Trial; Comparative Study; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't

[Publication-country] United States

[Chemical-registry-number] 0 / HFE protein, human; 0 / Histocompatibility Antigens Class I; 0 / Membrane Proteins

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] 672 patients with acinar cell carcinoma of the pancreas: a population-based comparison to pancreatic adenocarcinoma.

BACKGROUND: Acinar cell carcinoma (ACC) is a rare cancer of the pancreas accounting for approximately 1% of nonendocrine tumors.

OBJECTIVE: Our goal was to evaluate a large population-based cohort of patients with ACC and compare their demographic factors and outcomes to those of patients with pancreatic adenocarcinoma (PA).

The mean age at the time of diagnosis was significantly lower for ACC than PA (56 years vs 70 years, P < .001).

Multivariate Cox proportional hazards regression model results suggested patients with ACC were less likely to die (hazard ratio = 0.241; 95% confidence interval, 0.22-0.27) than patients with PA after controlling for gender, race, stage, SEER region of diagnosis, and surgical resection status.

[MeSH-major] Adenocarcinoma / pathology. Carcinoma, Acinar Cell / pathology. Pancreatic Neoplasms / pathology

MedlinePlus Health Information. consumer health - Pancreatic Cancer.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 18656619.001).

[ISSN] 1532-7361

[Journal-full-title] Surgery

[ISO-abbreviation] Surgery

[Language] eng

[Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't

[Publication-country] United States

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] MicroRNA expression patterns to differentiate pancreatic adenocarcinoma from normal pancreas and chronic pancreatitis.

CONTEXT: While global microRNA (miRNA) expression patterns of many embryologic, physiologic, and oncogenic processes have been described, description of the role of miRNAs in ductal adenocarcinoma of the pancreas is lacking.

OBJECTIVE: To define the expression pattern of miRNAs in pancreatic cancer and compare it with those of normal pancreas and chronic pancreatitis.

DESIGN AND SETTING: Specimens were obtained at a National Cancer Institute-designated comprehensive cancer center from patients with ductal adenocarcinoma of the pancreas (n = 65) or chronic pancreatitis (n = 42) (January 2000-December 2005).

All patients underwent curative pancreatectomy; those with pancreatic cancer were chemotherapy-naive.

RNA harvested from resected pancreatic cancers and matched benign adjacent pancreatic tissue as well as from chronic pancreatitis specimens was hybridized to miRNA microarrays.

MAIN OUTCOME MEASURES: Identification of differentially expressed miRNAs that could differentiate pancreatic cancer from normal pancreas, chronic pancreatitis, or both, as well as a pattern of miRNA expression predictive of long-term (>24 months) survival.

RESULTS: Twenty-one miRNAs with increased expression and 4 with decreased expression were identified that correctly differentiated pancreatic cancer from benign pancreatic tissue in 90% of samples by cross validation.

Fifteen overexpressed and 8 underexpressed miRNAs differentiated pancreatic cancer from chronic pancreatitis with 93% accuracy.

CONCLUSIONS: Pancreatic cancer may have a distinct miRNA expression pattern that may differentiate it from normal pancreas and chronic pancreatitis. miRNA expression patterns may be able to distinguish between long- and short-term survivors, but these findings need to be validated in other study populations.

Genetic Alliance. consumer health - Pancreatitis.

MedlinePlus Health Information. consumer health - Pancreatic Cancer.

COS Scholar Universe. author profiles.

[Email] Email this result item

Email the results to the following email address:   [X] Close

[CommentIn] JAMA. 2007 May 2;297(17):1923-5 [17473304.001]

(PMID = 17473300.001).

[ISSN] 1538-3598

[Journal-full-title] JAMA

[ISO-abbreviation] JAMA

[Language] ENG

[Grant] United States / NCI NIH HHS / CA / CA081534; United States / NCI NIH HHS / CA / CA128609

[Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural

[Publication-country] United States

[Chemical-registry-number] 0 / Genetic Markers; 0 / MicroRNAs; 0 / RNA, Neoplasm

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Stereotactic radiotherapy for unresectable adenocarcinoma of the pancreas.

BACKGROUND: The authors report on the local control and toxicity of stereotactic body radiotherapy (SBRT) for patients with unresectable pancreatic adenocarcinoma.

METHODS: Seventy-seven patients with unresectable adenocarcinoma of the pancreas received 25 gray (Gy) in 1 fraction.

CONCLUSIONS: SBRT for pancreatic adenocarcinoma was effective for local control with associated risk of toxicity and should be used with rigorous attention to quality assurance.

[MeSH-major] Adenocarcinoma / surgery. Pancreatic Neoplasms / surgery. Radiosurgery

MedlinePlus Health Information. consumer health - Pancreatic Cancer.

COS Scholar Universe. author profiles.

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Copyright] (c) 2008 American Cancer Society.

[CommentIn] Cancer. 2009 Feb 1;115(3):468-72 [19117338.001]

(PMID = 19117351.001).

[ISSN] 0008-543X

[Journal-full-title] Cancer

[ISO-abbreviation] Cancer

[Language] eng

[Publication-type] Journal Article; Research Support, Non-U.S. Gov't

[Publication-country] United States

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Effects of depression on the survival of pancreatic adenocarcinoma.

OBJECTIVES: Depression frequently predates the diagnosis of pancreatic adenocarcinoma.

The purpose of this study was to assess whether survival after resection for pancreatic cancer is shortened by the pretreatment presence of depression.

METHODS: A database of all patients diagnosed with pancreatic cancer was retrospectively reviewed for depression, resection, and chemotherapy and/or radiation therapy.

RESULTS: The median survival time for all depressed patients with pancreatic cancer was 5 months compared with 4 months for all nondepressed patients with pancreatic cancer (P < 0.9).

Depression, although common among patients with pancreatic cancer, does not affect survival.

[MeSH-major] Adenocarcinoma / psychology. Depression / epidemiology. Pancreatic Neoplasms / psychology

Genetic Alliance. consumer health - Depression.

MedlinePlus Health Information. consumer health - Depression.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 16340745.001).

[ISSN] 1536-4828

[Journal-full-title] Pancreas

[ISO-abbreviation] Pancreas

[Language] eng

[Publication-type] Comparative Study; Journal Article

[Publication-country] United States

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Gemcitabine and oxaliplatin in patients with pancreatic adenocarcinoma: clinical and pharmacokinetic data.

OBJECTIVES: This phase 2 study evaluated clinical efficacy, toxicity, and pharmacokinetics of combination gemcitabine (GEM) and oxaliplatin (OXA) in patients with advanced pancreatic adenocarcinoma.

CONCLUSIONS: The combination of GEM and OXA was well tolerated and showed a promising activity in patients with advanced pancreatic adenocarcinoma; no sequence-dependent pharmacokinetic interaction occurred when comparing the GEM-OXA versus the OXA-GEM sequence, with a 24-hour interval.

[MeSH-major] Adenocarcinoma / drug therapy. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Antineoplastic Combined Chemotherapy Protocols / toxicity. Deoxycytidine / analogs & derivatives. Organoplatinum Compounds / administration & dosage. Pancreatic Neoplasms / drug therapy

MedlinePlus Health Information. consumer health - Pancreatic Cancer.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 16340743.001).

[ISSN] 1536-4828

[Journal-full-title] Pancreas

[ISO-abbreviation] Pancreas

[Language] eng

[Publication-type] Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't

[Publication-country] United States

[Chemical-registry-number] 0 / Organoplatinum Compounds; 04ZR38536J / oxaliplatin; 0W860991D6 / Deoxycytidine; B76N6SBZ8R / gemcitabine

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Adenocarcinoma of the pancreas undetected by multidetector CT, endoscopic ultrasound, or intraoperative ultrasound.

CONTEXT: Patients with known or suspected pancreatic adenocarcinoma are typically evaluated with noninvasive imaging studies and endoscopic ultrasound.

Some patients have pancreatic adenocarcinomas that cannot be detected using any of these methods.

Multiple endoscopic ultrasound and triple phase pancreatic protocol CT exams were negative for a mass lesion and revealed a normal pancreas.

Intraoperative ultrasound of the pancreas was also felt to be normal.

Intraoperative biopsy of the head of the pancreas revealed a small, moderately to poorly differentiated adenocarcinoma, not visible on any of her imaging studies.

CONCLUSION: Some pancreatic adenocarcinomas may defy detection using modern imaging modalities.

[MeSH-major] Adenocarcinoma / diagnosis. Diagnostic Errors. Pancreatic Neoplasms / diagnosis

[MeSH-minor] Cholangiopancreatography, Endoscopic Retrograde / methods. Delayed Diagnosis. Endosonography / methods. Female. Humans. Intraoperative Period. Middle Aged. Tomography, X-Ray Computed / methods. Ultrasonography, Interventional

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 19734637.001).

[ISSN] 1590-8577

[Journal-full-title] JOP : Journal of the pancreas

[ISO-abbreviation] JOP

[Language] eng

[Publication-type] Case Reports; Journal Article

[Publication-country] Italy

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Orthovoltage intraoperative radiation therapy for pancreatic adenocarcinoma.

PURPOSE: To analyze the outcomes of patients from a single institution treated with surgery and orthovoltage intraoperative radiotherapy (IORT) for pancreatic adenocarcinoma.

Most tumors were located in the head of the pancreas (83%) and sites irradiated included: tumor bed (57%), vessels (26%), both the tumor bed/vessels (13%) and other (4%).

However, distant metastases remain the major problem for patients with pancreatic adenocarcinoma.

[MeSH-major] Adenocarcinoma / radiotherapy. Pancreatic Neoplasms / radiotherapy. Radiotherapy / methods

MedlinePlus Health Information. consumer health - Pancreatic Cancer.

MedlinePlus Health Information. consumer health - Radiation Therapy.

COS Scholar Universe. author profiles.

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Cites] Ann Surg. 1999 Dec;230(6):776-82; discussion 782-4 [10615932.001]

[Cites] Int J Radiat Oncol Biol Phys. 2010 Jul 1;77(3):734-42 [20207498.001]

[Cites] Lancet. 2001 Nov 10;358(9293):1576-85 [11716884.001]

[Cites] Am J Clin Oncol. 2003 Feb;26(1):16-21 [12576918.001]

[Cites] Surg Oncol Clin N Am. 2003 Oct;12(4):899-924 [14989123.001]

[Cites] N Engl J Med. 2004 Mar 18;350(12):1200-10 [15028824.001]

[Cites] N Engl J Med. 2004 Mar 18;350(12):1249-51 [15028829.001]

[Cites] Lancet. 2004 Mar 27;363(9414):1049-57 [15051286.001]

[Cites] Int J Radiat Oncol Biol Phys. 1984 Oct;10(10):1957-65 [6490425.001]

[Cites] Arch Surg. 1985 Aug;120(8):899-903 [4015380.001]

[Cites] Int J Radiat Oncol Biol Phys. 1986 Feb;12(2):255-9 [3949576.001]

[Cites] Cancer. 1987 Jun 15;59(12):2006-10 [3567862.001]

[Cites] Arch Surg. 1989 Jan;124(1):127-32 [2910241.001]

[Cites] Int J Pancreatol. 1990 Aug-Nov;7(1-3):195-200 [2081924.001]

[Cites] Cancer. 1994 Jun 15;73(12):2930-5 [8199990.001]

[Cites] Ann Surg. 1995 Jun;221(6):721-31; discussion 731-3 [7794076.001]

[Cites] Br J Cancer. 1997;76(11):1474-9 [9400944.001]

[Cites] J Hepatobiliary Pancreat Surg. 1998;5(3):227-34 [9880768.001]

[Cites] Int J Radiat Oncol Biol Phys. 2005 Mar 15;61(4):965-6 [15752874.001]

[Cites] CA Cancer J Clin. 2006 Mar-Apr;56(2):106-30 [16514137.001]

[Cites] Acta Oncol. 2006;45(2):124-35 [16546857.001]

[Cites] Semin Oncol. 2007 Aug;34(4):335-46 [17674962.001]

[Cites] Int J Radiat Oncol Biol Phys. 2007 Oct 1;69(2):504-11 [17560736.001]

[Cites] Int J Radiat Oncol Biol Phys. 2008 Mar 15;70(4):1094-9 [18313525.001]

[Cites] Radiother Oncol. 2008 Jun;87(3):318-25 [18199514.001]

[Cites] J Clin Oncol. 2008 Jul 20;26(21):3503-10 [18640931.001]

[Cites] J Clin Oncol. 2008 Jul 20;26(21):3511-6 [18640932.001]

[Cites] Radiother Oncol. 2009 Apr;91(1):54-9 [18762346.001]

[Cites] J Clin Oncol. 2009 Jun 10;27(17):2855-62 [19398572.001]

[Cites] Ann Surg Oncol. 2009 Aug;16(8):2116-22 [19437078.001]

[Cites] Int J Radiat Oncol Biol Phys. 2001 Jul 1;50(3):651-8 [11395232.001]

(PMID = 21059255.001).

[ISSN] 1748-717X

[Journal-full-title] Radiation oncology (London, England)

[ISO-abbreviation] Radiat Oncol

[Language] eng

[Publication-type] Journal Article; Research Support, Non-U.S. Gov't

[Publication-country] England

[Other-IDs] NLM/ PMC2987939

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Metastatic gastric tumor secondary to pancreatic adenocarcinoma.

Metastatic disease, from the pancreas, involving the stomach is an unusual clinical event.

Local recurrence, liver metastases, and peritoneal spread are the most common recurrent patterns after curative resection of pancreatic cancer.

We report a patient who suffered from gastric metastasis secondary to pancreatic adenocarcinoma 1 year after pancreatectomy.

A 49-year-old woman underwent distal pancreatectomy with intraoperative radiation therapy for cancer of the body of the pancreas in October 2002.

The histological diagnosis was well-differentiated adenocarcinoma of the pancreas, stage IIB; T1N1M0.

Histological diagnosis of the biopsy specimen was well-differentiated adenocarcinoma, and immunohistochemical studies, using anti-cytokeratin 7 and -20 monoclonal antibodies, were compatible with gastric metastasis from pancreatic carcinoma.

Histopatholoical examination of the resected specimen revealed submucosal growth of the metastatic cancer (well-differentiated adenocarcinoma).

[MeSH-major] Adenocarcinoma / secondary. Pancreatic Neoplasms / pathology. Stomach Neoplasms / secondary

MedlinePlus Health Information. consumer health - Pancreatic Cancer.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 15770407.001).

[ISSN] 0944-1174

[Journal-full-title] Journal of gastroenterology

[ISO-abbreviation] J. Gastroenterol.

[Language] eng

[Publication-type] Case Reports; Journal Article

[Publication-country] Japan

[Chemical-registry-number] 0 / CA-19-9 Antigen

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Impact of resection status on pattern of failure and survival after pancreaticoduodenectomy for pancreatic adenocarcinoma.

OBJECTIVE: To better understand the impact of a microscopically positive margin (R1) on patterns of disease recurrence and survival after pancreaticoduodenectomy (PD) for pancreatic adenocarcinoma.

Standard pathologic evaluation of the PD specimen included permanent section analysis of the final bile duct, pancreatic, and superior mesenteric artery (SMA) margins.

Survival and follow-up were calculated from the date of initial histologic diagnosis to the dates of first recurrence or death and last contact, respectively.

RESULTS: PD was performed on 360 consecutive patients with pancreatic adenocarcinoma.

MedlinePlus Health Information. consumer health - Pancreatic Cancer.

COS Scholar Universe. author profiles.

ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .

NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Cites] Chir Ital. 2000 May-Jun;52(3):263-70 [10932371.001]

[Cites] Ann Surg Oncol. 2001 Mar;8(2):123-32 [11258776.001]

[Cites] J Gastrointest Surg. 2000 Nov-Dec;4(6):567-79 [11307091.001]

[Cites] Ann Surg. 2001 Jul;234(1):47-55 [11420482.001]

[Cites] Ann Surg. 2001 Dec;234(6):758-68 [11729382.001]

[Cites] J Clin Oncol. 2002 May 15;20(10):2537-44 [12011133.001]

[Cites] AJR Am J Roentgenol. 2003 May;180(5):1311-23 [12704043.001]

[Cites] Eur J Surg Oncol. 1991 Apr;17(2):173-81 [2015922.001]

[Cites] Ann Surg. 1993 Feb;217(2):144-8 [8094952.001]

[Cites] Ann Surg. 1995 Jan;221(1):59-66 [7826162.001]

[Cites] Ann Surg. 1995 Jun;221(6):721-31; discussion 731-3 [7794076.001]

[Cites] Br J Surg. 1996 May;83(5):625-31 [8689203.001]

[Cites] Pancreas. 1996 May;12(4):373-80 [8740405.001]

[Cites] Int J Radiat Oncol Biol Phys. 1997 Aug 1;39(1):39-49 [9300738.001]

[Cites] Am Surg. 1999 Jul;65(7):618-23; discussion 623-4 [10399969.001]

[Cites] J Gastrointest Surg. 2004 Dec;8(8):935-49; discussion 949-50 [15585381.001]

[Cites] Br J Surg. 2006 Oct;93(10):1232-7 [16804874.001]

[CommentIn] Ann Surg. 2008 Apr;247(4):716-7 [18362643.001]

(PMID = 17592291.001).

[ISSN] 0003-4932

[Journal-full-title] Annals of surgery

[ISO-abbreviation] Ann. Surg.

[Language] ENG

[Grant] United States / NCI NIH HHS / CA / P20 CA101936; United States / NCI NIH HHS / CA / 1 P20 CA101936-01

[Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't

[Publication-country] United States

[Other-IDs] NLM/ PMC1899216